Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-28T03:09:00.074Z Has data issue: false hasContentIssue false
  • English
  • Français

Selegiline in the Treatment of Negative Symptoms of Schizophrenia

Published online by Cambridge University Press:  15 February 2006

Allison Lin  and
J. Alexander Bodkin
Allison Lin
Affiliation:
Clinical Psychopharmacology Research Program, McLean Hospital, Harvard Medical School; Email: abodkin@mclean.harvard.edu
J. Alexander Bodkin
Affiliation:
Clinical Psychopharmacology Research Program, McLean Hospital, Harvard Medical School; Email: abodkin@mclean.harvard.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Selegilineschizophrenianegative symptomsneurotherapeuticsclinical trial
Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 1 , Issue 1 , January 2006 , pp. 121 - 131
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adan, F., & Siris, S.G. (1989). Trials of adjunctive alprazolam in negative symptom patients. Canadian Journal of Psychiatry, 34, 326–328.Google Scholar
Amsterdam, J.D. (2003). A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Journal of Clinical Psychiatry, 64, 208–214.Google Scholar
Andreasen, N.C. (1982). Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry, 39,784–788.Google Scholar
Ayd, F.J., & Blackwell, B. (eds.) (1970). Discoveries in Biological Psychiatry. Philadelphia: Lippincott.
Bermanzohn, P.C., & Siris, S.G. (1992). Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Comprehensive Psychiatry, 33, 221–232.Google Scholar
Bodkin, J.A. (1990). Emerging uses for high-potency benzodiazepines in psychotic disorders. Journal of Clinical Psychiatry, 55 (Suppl.), 41–46.Google Scholar
Bodkin, J.A., & Amsterdam, J.D. (2002). Transdermal selegiline in major depression: a double-blind, placebo-controlled study in outpatients. American Journal of Psychiatry, 195, 1869–1875.Google Scholar
Bodkin, J.A., & Kwon, A.E. (2001). Selegiline and other atypical monoamine oxidase inhibitors in depression. Psychiatric Annals, 31, 385–391.Google Scholar
Bodkin, J.A., Cohen, B.M., Solomon, M.S., Cannon, S.E., Zornberg, G.L., & Cole, J.O. (1996). Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. The Journal of Nervous and Mental Disease, 184, 295–301.Google Scholar
Bodkin, J.A., Siris, S.G., Bermanzohn, P.C., Hennen, J., & Cole, J.O. (2005). Treating negative symptoms of schizophrenic outpatients by selegiline augmentation of antipsychotic medication: a multi-center, double-blind, placebo-controlled trial. American Journal of Psychiatry, 162, 388–390.Google Scholar
Bucci, L. (1987). The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology, 91, 104–108.Google Scholar
Carpenter, W.T., Heinrichs, D.W., Wagman, A.M., & Althea, M.I. (1988). Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry, 145, 578–583.Google Scholar
Cole, J.O., Jones, R.T., & Klerman, G.L. (1961). Drug therapy. Progress in Neurology and Psychiatry, 16, 539–574.Google Scholar
Davis, K.L., Kahn, R.S., Ko, G., & Davidson, M. (1991). Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry, 148, 1474–1486.Google Scholar
Goff, D.C., Renshaw, P.F., Sarid-Segal, O., Dreyfus, D., Amico, E.T., & Ciraulo, D.A. (1993). A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biological Psychiatry, 33, 700–706.Google Scholar
Goff, D.C., Midha, K.K., Sarid-Segal, O., Hubbard, J.W., & Amico, E.T. (1995). A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology, 117, 417–423.Google Scholar
Gray, J.A. (1991). Neural systems, emotion and personality. In: Madden, J. (ed.), Neurobiology of Learning, Emotion and Affect. New York: Raven Press, pp. 273–306.
Gupta, S., Droney, T., Kyser, A., & Keller, P. (1999). Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Comprehensive Psychiatry, 40, 148–150.Google Scholar
Jungerman, T., Rabinowitz, D., & Klein, E. (1999). Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study. Journal of Clinical Psychopharmacology, 19, 522–525.Google Scholar
Kamman, G.R., Freeman, J.G., & Lucero, R. (1953). The effect of iproniazid on the behavior of long-term mental patients. Journal of Nervous and Mental Disease, 118, 391–407.Google Scholar
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H.Y. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.Google Scholar
Klein, D.F., Gittelman, R., Quitkin, F., & Rifkin, A. (1980). Diagnosis and Drug Treatment of Psychiatric Disorders: adults and Children (2nd ed.). Baltimore, MD: Williams & Wilkins.
Knoll, J. (1983). Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurologica Scandinavia, 95 (Suppl.), 57–80.Google Scholar
Lees, A. (1991). Selegiline hydrochloride and cognition. Acta Neurologica Scandanavia, 136 (Suppl.), 91–94.Google Scholar
Levi-Minzi, S., Bermanzohn, P.C., & Siris, S.G. (1991). Bromocriptine for “negative” schizophrenia. Comprehensive Psychiatry, 32, 210–216.Google Scholar
Mandel, S., Grunblatt, E., Riederer, P., Gerlach, M., Levites, Y., & Youdim, M.B. (2003). Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs, 17 (10), 729–762.Google Scholar
Mann, J.J., Aarons, S.F., Wilner, P.J., Keilp, J.G., Sweeney, J.A., Pearlstein, T., Francis, A.J., Kocsis, J.H., & Brown, R.P. (1989). A controlled study of the antidepressant efficacy and side effects of (−)-deprenyl. A selective monoamine oxidase inhibitor. Archives of General Psychiatry, 46, 45–50.Google Scholar
McEvoy, J.P., Freudenreich, O., & Wilson, W.H. (1999). Smoking and therapeutic response to clozapine in patients with schizophrenia. Biological Psychiatry, 46, 125–129.Google Scholar
Perenyi, A., Goswami, U., Frecska, E., Arato, M., & Bela, A. (1991). L-deprenyl in treating negative symptoms of schizophrenia. Psychiatry Research, 42, 188–191.Google Scholar
Rifkin, A., Quitkin, F., & Klein, D.F. (1975). Akinesia: a poorly recognized drug-induced extrapyramidal disorder. Archives of General Psychiatry, 32, 672–675.Google Scholar
Silver, H., & Nassar, A. (1992). Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biological Psychiatry, 31, 698–704.Google Scholar
Siris, S.G., van Kammen, D.P., & Docherty, J.P. (1978). The use of anti-depressant medications in schizophrenia: a review of the literature. Archives of General Psychiatry, 35, 1368–1377.Google Scholar
Tetrud, J.W., & Langston, J.W. (1989). The effect of Deprenyl (Selegiline) on the natural history of Parkinson's disease. Science, 245, 519–522.Google Scholar
Watson, D., Clark, L.A., & Tellegen, A. (1988). Development and validation of brief measures of positive and negative affect: the PANAS scales. Journal of Personality and Social Psychology, 54, 1063–1070.Google Scholar
Wirshing, D.A. (2001). Adverse effects of atypical antipsychotics. Journal of Clinical Psychiatry, 62 (Suppl.), 7–10.Google Scholar